ADA Scientific Sessions 2026 Abstract
Zenagamtide (Amycretin), a Novel Unimolecular GLP-1 and Amylin Receptor Agonist: Phase 2b Results in T2D
Trial in peopleInterventions
Papers by Marisse Asong
2 results
- ADA Scientific Sessions 2025 Abstract
CGM-Derived Model-Based Postprandial Glucose with IcoSema vs. Other Insulin Regimens—A Post Hoc Analysis of COMBINE 1 and 3
Trial in peopleInterventions